News & Updates

Show Multimedia Only

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024 by

In a phase IIb open-label trial, combination therapy with bulevirtide and peginterferon alfa-2a (pegIFNα) yields a synergistic on-treatment effect, with more patients achieving undetectable HDV RNA levels compared to bulevirtide alone.

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024

Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC

14 Jun 2024 by

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.

Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC

14 Jun 2024

Daromun plus surgery improves survival in resectable melanoma

14 Jun 2024 by

Use of neoadjuvant daromun in addition to surgery is safe and provides survival benefits in patients with resectable, locally advanced melanoma, results of the PIVOTAL study have shown.

Daromun plus surgery improves survival in resectable melanoma

14 Jun 2024

Nivolumab plus chemo offers prolonged survival in resectable NSCLC

14 Jun 2024 by

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

Nivolumab plus chemo offers prolonged survival in resectable NSCLC

14 Jun 2024

Valproate exposure during spermatogenesis carries no harm in offspring

14 Jun 2024

Exposure to valproate during spermatogenesis does not appear to put infants at risk of congenital malformations or neurodevelopmental disorders, including autism spectrum disorder, according to a study.

Valproate exposure during spermatogenesis carries no harm in offspring

14 Jun 2024

Melatonin use linked to lower AMD risk

13 Jun 2024

The use of melatonin appears to exert some protective effect on the risk of age-related macular degeneration (AMD) incidence and progression, as suggested in a retrospective cohort study.